triethoxy-[2-(7-oxabicyclo[4.1.0]heptan-4-yl)ethyl]silane

We are triethoxy-[2-(7-oxabicyclo[4.1.0]heptan-4-yl)ethyl]silane CAS:10217-34-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Chemical Name:triethoxy-[2-(7-oxabicyclo[4.1.0]heptan-4-yl)ethyl]silane
CAS.NO:10217-34-2
Synonyms:triethoxy-[2-(3,4-epoxy-cyclohexyl)-ethyl]-silane; 2-(2,2,3,3-TETRAFLUOROPROPANOYL)CYCLOPENTANONE; Triaethoxy-[2-(3,4-epoxy-cyclohexyl)-aethyl]-silan; 7-Oxabicyclo(4.1.0)heptane,3-(2-(triethoxysilyl)ethyl);
Molecular Formula:C14H28O4Si
Molecular Weight:288.45500
 
Physical and Chemical Properties:
Density:1.002;
Boiling point:316.3^oC;
Flash point:117.7^oC;
Index of Refraction:1.4455;
 
Specification:
Appearance:Colorless clear liquid
Purity(GC):≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It can be used in waterborne coating formulations, to improve solvent, impact and mar resistance, wet and dry adhesion, also stain resistance in wood and automotive plastic coatings.




Related News: Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.2,3-Dichloro-5,6-dicyano-1,4-benzoquinone CAS:84-58-2 Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.allyl alcohol China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.(2S,3aR,7aS)-2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid,hydrochloride China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.